FDA Grants Priority Review to Expand Liso-Cel Indications in R/R Follicular Lymphoma and MCL
OncLive,
Anne Kerber, MD The FDA has granted priority review to 2 supplemental biologics license applications (sBLAs) for lisocabtagene…
Patient-Reported Outcomes (PROs) from the Phase 2 TRANSCEND FL Study of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL)
Overview of attention for article published in Blood, November 2023
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
Good Attention Score compared to outputs of the same age (76th percentile)
-
Good Attention Score compared to outputs of the same age and source (68th percentile)
Readers on
- mendeley
- 1 Mendeley